Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2013

Open Access 01-12-2013 | Research

Pulmonary biomarkers in COPD exacerbations: a systematic review

Authors: Angela Koutsokera, Konstantinos Kostikas, Laurent P Nicod, Jean-William Fitting

Published in: Respiratory Research | Issue 1/2013

Login to get access

Abstract

Exacerbations of COPD (ECOPD) represent a major burden for patients and health care systems. Innovative sampling techniques have led to the identification of several pulmonary biomarkers. Although some molecules are promising, their usefulness in clinical practice is not yet established. Medline and Highwire databases were used to identify studies evaluating pulmonary sampled biomarkers in ECOPD. We combined 3 terms for ECOPD, 3 for biomarkers and 6 for the sampling method. Seventy-nine studies were considered eligible for inclusion in the review and were analyzed further. Pulmonary biomarkers sampled with non-invasive, semi-invasive and invasive methods were evaluated for their potential to illustrate the disease’s clinical course, to correlate to clinical variables and to predict clinical outcomes, ECOPD etiology and response to treatment. According to published data several pulmonary biomarkers assessed in ECOPD have the potential to illustrate the natural history of disease through the modification of their levels. Among the clinically relevant molecules, those that have been studied the most and appear to be promising are spontaneous and induced sputum biomarkers for reflecting clinical severity and symptomatic recovery, as well as for directing towards an etiological diagnosis. Current evidence on the clinical usefulness of exhaled breath condensate and bronchoalveolar lavage biomarkers in ECOPD is limited. In conclusion, pulmonary biomarkers have the potential to provide information on the mechanisms underlying ECOPD, and several correlate with clinical variables and outcomes. However, on the basis of published evidence, no single molecule is adequately validated for wide clinical use. Clinical trials that incorporate biomarkers in decisional algorithms are required.
Appendix
Available only for authorised users
Literature
1.
Burge S, Wedzicha JA: COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003, 41: 46s-53s.PubMedCrossRef
2.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-469. 10.1183/09031936.00099306.PubMedCrossRef
3.
Group BDW: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69: 89-95.CrossRef
4.
Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, Van Beurden WJ, Corradi M, Dekhuijzen R, et al: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005, 26: 523-548. 10.1183/09031936.05.00029705.PubMedCrossRef
5.
Koutsokera A, Loukides S, Gourgoulianis KI, Kostikas K: Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem. 2008, 15: 620-630. 10.2174/092986708783769768.PubMedCrossRef
6.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151: 264-269. 10.7326/0003-4819-151-4-200908180-00135. W264PubMedCrossRef
7.
Koutsokera A, Stolz D, Loukides S, Kostikas K: Systemic biomarkers in exacerbations of copd: the evolving clinical challenge. Chest. 2012, 141: 396-405. 10.1378/chest.11-0495.PubMedCrossRef
8.
Shorter JH, Nelson DD, McManus JB, Zahniser MS, Sama SR, Milton DK: Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO(2), CO and N(2)O) by infrared laser spectroscopy. J Breath Res. 2011, 5: 037108-10.1088/1752-7155/5/3/037108.PubMedPubMedCentralCrossRef
9.
Ropcke S, Holz O, Lauer G, Muller M, Rittinghausen S, Ernst P, Lahu G, Elmlinger M, Krug N, Hohlfeld JM: Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One. 2012, 7: e46207-10.1371/journal.pone.0046207.PubMedPubMedCentralCrossRef
10.
Agusti AG, Villaverde JM, Togores B, Bosch M: Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1999, 14: 523-528. 10.1034/j.1399-3003.1999.14c08.x.PubMedCrossRef
11.
Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J. 2001, 22: 249-253.PubMed
12.
Antus B, Barta I, Horvath I, Csiszer E: Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology. 2010, 15: 472-477. 10.1111/j.1440-1843.2010.01711.x.PubMedCrossRef
13.
Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, Csiszer E: Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. Am J Respir Crit Care Med. 2010, 182: 1492-1497. 10.1164/rccm.201003-0451OC.PubMedCrossRef
14.
Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA: Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J. 2005, 26: 1009-1015. 10.1183/09031936.05.00047305.PubMedCrossRef
15.
Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A: Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009, 64: 424-429. 10.1136/thx.2008.103432.PubMedCrossRef
16.
Kersul AL, Iglesias A, Rios A, Noguera A, Forteza A, Serra E, Agusti A, Cosio BG: Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2011, 47: 176-183.PubMedCrossRef
17.
Lazar Z, Huszar E, Kullmann T, Barta I, Antus B, Bikov A, Kollai M, Horvath I: Adenosine triphosphate in exhaled breath condensate of healthy subjects and patients with chronic obstructive pulmonary disease. Inflamm Res. 2008, 57: 367-373. 10.1007/s00011-008-8009-6.PubMedCrossRef
18.
Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006, 173: 1114-1121. 10.1164/rccm.200506-859OC.PubMedCrossRef
19.
Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA: Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005, 26: 52-59. 10.1183/09031936.04.00125304.PubMedCrossRef
20.
Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ: Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157: 998-1002. 10.1164/ajrccm.157.3.97-05009.PubMedCrossRef
21.
Trischler J, Merkel N, Konitzer S, Muller CM, Unverzagt S, Lex C: Fractionated breath condensate sampling: H2O2 concentrations of the alveolar fraction may be related to asthma control in children. Respir Res. 2012, 13: 14-10.1186/1465-9921-13-14.PubMedPubMedCentralCrossRef
22.
Moller W, Heimbeck I, Weber N, Khadem Saba G, Korner B, Neiswirth M, Kohlhaufl M: Fractionated exhaled breath condensate collection shows high hydrogen peroxide release in the airways. J Aerosol Med Pulm Drug Deliv. 2010, 23: 129-135. 10.1089/jamp.2009.0764.PubMedCrossRef
23.
Tateosian NL, Costa MJ, Guerrieri D, Barro A, Mazzei JA, Eduardo Chuluyan H: Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. Cytokine. 2012, 58: 361-367. 10.1016/j.cyto.2012.03.006.PubMedCrossRef
24.
Gessner C, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, Engelmann L, Hoheisel G, Gillissen A, Sack U, Wirtz H: Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med. 2005, 99: 1229-1240. 10.1016/j.rmed.2005.02.041.PubMedCrossRef
25.
Mazur W, Stark H, Sovijarvi A, Myllarniemi M, Kinnula VL: Comparison of 8-isoprostane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers. Respiration. 2009, 78: 209-216. 10.1159/000206010.PubMedCrossRef
26.
Zakharkina T, Koczulla AR, Mardanova O, Hattesohl A, Bals R: Detection of microorganisms in exhaled breath condensate during acute exacerbations of COPD. Respirology. 2011, 16: 932-938. 10.1111/j.1440-1843.2011.01977.x.PubMedCrossRef
27.
Gerritsen WB, Asin J, Zanen P, van den Bosch JM, Haas FJ: Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir Med. 2005, 99: 84-90. 10.1016/j.rmed.2004.04.017.PubMedCrossRef
28.
Oudijk EJ, Gerritsen WB, Nijhuis EH, Kanters D, Maesen BL, Lammers JW, Koenderman L: Expression of priming-associated cellular markers on neutrophils during an exacerbation of COPD. Respir Med. 2006, 100: 1791-1799. 10.1016/j.rmed.2006.01.022.PubMedCrossRef
29.
Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Gorski P: Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci. 2012, 8: 277-285.PubMedPubMedCentralCrossRef
30.
Koczulla AR, Noeske S, Herr C, Koepke J, Jorres RA, Nell C, Schmid S, Vogelmeier C, Bals R: Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir Med. 2012, 106: 120-126. 10.1016/j.rmed.2011.06.015.PubMedCrossRef
31.
Carpagnano GE, Resta O, Foschino-Barbaro MP, Spanevello A, Stefano A, Di Gioia G, Serviddio G, Gramiccioni E: Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol. 2004, 505: 169-175. 10.1016/j.ejphar.2004.10.007.PubMedCrossRef
32.
Ko FW, Leung TF, Wong GW, Ngai JC, To KW, Ng S, Hui DS: Measurement of tumor necrosis factor-α, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J COPD. 2009, 4: 79-86.
33.
34.
Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax. 2003, 58: 294-298. 10.1136/thorax.58.4.294.PubMedPubMedCentralCrossRef
35.
Warwick G, Thomas PS, Yates DH: Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology. 2013, PMID: 11120902
36.
Ko FW, Leung TF, Wong GW, Ngai J, To KW, Ng S, Hui DS: Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2009, 4: 79-86.PubMedPubMedCentral
37.
Koutsokera A, Kiropoulos TS, Nikoulis DJ, Daniil ZD, Tsolaki V, Tanou K, Papaioannou AI, Germenis A, Gourgoulianis KI, Kostikas K: Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med. 2009, 103: 919-926. 10.1016/j.rmed.2008.12.006.PubMedCrossRef
38.
Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 118: 1557-1565. 10.1378/chest.118.6.1557.PubMedCrossRef
39.
Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF: Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177: 491-497. 10.1164/rccm.200708-1234OC.PubMedCrossRef
40.
Parameswaran GI, Sethi S, Murphy TF: Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest. 2011, 140: 611-617. 10.1378/chest.10-2760.PubMedPubMedCentralCrossRef
41.
Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA: Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007, 29: 527-534. 10.1183/09031936.00092506.PubMedCrossRef
42.
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987, 106: 196-204. 10.7326/0003-4819-106-2-196.PubMedCrossRef
43.
Tsimogianni AM, Papiris SA, Kanavaki S, Stathopoulos GT, Sotiropoulou C, Manali ED, Michalopoulou P, Roussos C, Kotanidou A: Predictors of positive sputum cultures in exacerbations of chronic obstructive pulmonary disease. Respirology. 2009, 14: 1114-1120. 10.1111/j.1440-1843.2009.01615.x.PubMedCrossRef
44.
Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, Telgen MC, van der Palen J, Hendrix MG, van der Valk PD: Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med. 2009, 103: 601-606. 10.1016/j.rmed.2008.10.012.PubMedCrossRef
45.
Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P: Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J. 2012, 39: 1354-1360. 10.1183/09031936.00042111.PubMedCrossRef
46.
Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA: Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006, 173: 71-78. 10.1164/rccm.200505-704OC.PubMedCrossRef
47.
Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 2000, 15: 274-280. 10.1034/j.1399-3003.2000.15b09.x.PubMedCrossRef
48.
Dal Negro RW, Micheletto C, Tognella S, Visconti M, Guerriero M, Sandri MF: A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations. COPD. 2005, 2: 7-16. 10.1081/COPD-200050680.PubMedCrossRef
49.
White AJ, Gompertz S, Bayley DL, Hill SL, O’Brien C, Unsal I, Stockley RA: Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003, 58: 680-685. 10.1136/thorax.58.8.680.PubMedPubMedCentralCrossRef
50.
De Burbure C, Pignatti P, Corradi M, Malerba M, Clippe A, Dumont X, Moscato G, Mutti A, Bernard A: Uteroglobin-related protein 1 and clara cell protein in induced sputum of patients with asthma and rhinitis. Chest. 2007, 131: 172-179. 10.1378/chest.06-0835.PubMedCrossRef
51.
Bathoorn E, Liesker J, Postma D, Koeter G, Van Oosterhout AJ, Kerstjens HA: Safety of sputum induction during exacerbations of COPD. Chest. 2007, 131: 432-438. 10.1378/chest.06-2216.PubMedCrossRef
52.
Gao P, Gibson PG, Zhang J, He X, Hao Y, Li P, Liu H: The Safety of sputum induction in adults with acute exacerbation of COPD. Clin Respir J. 2012, PMID: 17136956
53.
Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000, 55: 114-120. 10.1136/thorax.55.2.114.PubMedPubMedCentralCrossRef
54.
Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA: Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000, 16: 677-683. 10.1034/j.1399-3003.2000.16d19.x.PubMedCrossRef
55.
Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 163: 349-355. 10.1164/ajrccm.163.2.2003122.PubMedCrossRef
56.
Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, et al: Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011, 183: 734-742. 10.1164/rccm.201006-0833OC.PubMedPubMedCentralCrossRef
57.
Bathoorn E, Liesker JJ, Postma DS, Koeter GH, van der Toorn M, van der Heide S, Ross HA, Van Oosterhout AJ, Kerstjens HA: Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009, 4: 101-109.PubMedPubMedCentralCrossRef
58.
Bathoorn E, Liesker JJ, Postma DS, Boorsma M, Bondesson E, Koeter GH, Kauffman HF, Van Oosterhout AJ, Kerstjens HA: Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD. 2008, 5: 282-290. 10.1080/15412550802363360.PubMedCrossRef
59.
Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al: Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011, 184: 662-671. 10.1164/rccm.201104-0597OC.PubMedCrossRef
60.
He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN: Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010, 80: 445-452. 10.1159/000321374.PubMedCrossRef
61.
Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994, 150: 1646-1652. 10.1164/ajrccm.150.6.7952628.PubMedCrossRef
62.
Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 117: 380S-385S. 10.1378/chest.117.5_suppl_2.380S.PubMedCrossRef
63.
Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA: Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006, 129: 317-324. 10.1378/chest.129.2.317.PubMedCrossRef
64.
Pant S, Walters EH, Griffiths A, Wood-Baker R, Johns DP, Reid DW: Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology. 2009, 14: 495-503. 10.1111/j.1440-1843.2009.01517.x.PubMedCrossRef
65.
Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005, 60: 293-300. 10.1136/thx.2004.027946.PubMedPubMedCentralCrossRef
66.
Maestrelli P, Saetta M, Di Stefano A, Calcagni PG, Turato G, Ruggieri MP, Roggeri A, Mapp CE, Fabbri LM: Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med. 1995, 152: 1926-1931. 10.1164/ajrccm.152.6.8520757.PubMedCrossRef
67.
Singh M, Lee SH, Porter P, Xu C, Ohno A, Atmar RL, Greenberg SB, Bandi V, Gern J, Amineva S: Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010, 125: 1369-1378. 10.1016/j.jaci.2010.02.035. e1362PubMedPubMedCentralCrossRef
68.
Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL: An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res. 2006, 7: 116-10.1186/1465-9921-7-116.PubMedPubMedCentralCrossRef
69.
Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, Wark PA, Hutchinson A, Irving LB, Levy BD, Anderson GP: Serum amyloid A opposes lipoxin A to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012, 109: 935-940. 10.1073/pnas.1109382109.PubMedPubMedCentralCrossRef
70.
Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, Fabiano F: Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J. 1997, 10: 846-850.PubMed
71.
Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK: Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003, 168: 968-975. 10.1164/rccm.200208-794OC.PubMedCrossRef
72.
Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM: Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy. 1996, 26: 766-774. 10.1111/j.1365-2222.1996.tb00606.x.PubMedCrossRef
73.
Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK: Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med. 2001, 164: 109-116. 10.1164/ajrccm.164.1.2007050.PubMedCrossRef
74.
Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D: Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy. 2002, 57: 17-22.PubMed
75.
De Laurentiis G, Maniscalco M, Cianciulli F, Stanziola A, Marsico S, Lundberg JO, Weitzberg E, Sofia M: Exhaled nitric oxide monitoring in COPD using a portable analyzer. Pulm Pharmacol Ther. 2008, 21: 689-693. 10.1016/j.pupt.2008.04.006.PubMedCrossRef
76.
Basanta M, Ibrahim B, Dockry R, Douce D, Morris M, Singh D, Woodcock A, Fowler SJ: Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012, 13: 72-10.1186/1465-9921-13-72.PubMedPubMedCentralCrossRef
77.
Liesker JJ, Bathoorn E, Postma DS, Vonk JM, Timens W, Kerstjens HA: Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011, 105: 1853-1860. 10.1016/j.rmed.2011.07.002.PubMedCrossRef
78.
Tumkaya M, Atis S, Ozge C, Delialioglu N, Polat G, Kanik A: Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2007, 101: 729-737. 10.1016/j.rmed.2006.08.020.PubMedCrossRef
79.
Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA: Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J. 2012, 39: 721-729. 10.1183/09031936.00022011.PubMedCrossRef
80.
Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID: Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007, 29: 906-913. 10.1183/09031936.00146306.PubMedCrossRef
81.
Bazeghi N, Gerds TA, Budtz-Jorgensen E, Hove J, Vestbo J: Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. Respir Med. 2011, 105: 1338-1344. 10.1016/j.rmed.2011.03.015.PubMedCrossRef
82.
Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, Kinose D, Ogawa E, Hoshino Y, Niimi A, et al: Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008, 63: 951-955. 10.1136/thx.2007.092858.PubMedCrossRef
83.
Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001, 56: 36-41. 10.1136/thorax.56.1.36.PubMedPubMedCentralCrossRef
84.
Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002, 57: 759-764. 10.1136/thorax.57.9.759.PubMedPubMedCentralCrossRef
85.
Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA: Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001, 56: 30-35. 10.1136/thorax.56.1.30.PubMedPubMedCentralCrossRef
86.
Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005, 128: 1995-2004. 10.1378/chest.128.4.1995.PubMedCrossRef
87.
Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, Andersson B: Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax. 1995, 50: 360-365. 10.1136/thx.50.4.360.PubMedPubMedCentralCrossRef
88.
Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006, 24: 971-983. 10.1038/nbt1235.PubMedCrossRef
89.
Koulman A, Lane GA, Harrison SJ, Volmer DA: From differentiating metabolites to biomarkers. Anal Bioanal Chem. 2009, 394: 663-670. 10.1007/s00216-009-2690-3.PubMedPubMedCentralCrossRef
90.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, De Vet HC, Lijmer JG, Standards for Reporting of Diagnostic A: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003, 138: W1-12. 10.7326/0003-4819-138-1-200301070-00012-w1.PubMedCrossRef
Metadata
Title
Pulmonary biomarkers in COPD exacerbations: a systematic review
Authors
Angela Koutsokera
Konstantinos Kostikas
Laurent P Nicod
Jean-William Fitting
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2013
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-14-111

Other articles of this Issue 1/2013

Respiratory Research 1/2013 Go to the issue

Research

Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey

Research

Cigarette smoke enhances human rhinovirus-induced CXCL8 production via HuR-mediated mRNA stabilization in human airway epithelial cells

Research

Aggravation of myocardial dysfunction by injurious mechanical ventilation in LPS-induced pneumonia in rats

Research

Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury

Research

Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010

Research

Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits